| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chitosan — Chitosan is a deacetylated chitin-derived cationic polysaccharide used as a biocompatible biomaterial, immune-active adjuvant, and multifunctional delivery polymer rather than a standard standalone cytotoxic anticancer drug. Its formal classification is a natural polymeric biomaterial and drug-delivery excipient/platform. Standard abbreviations include CS; related derivatives include chitooligosaccharides and glycated chitosan in some oncology contexts. It is typically sourced from crustacean shells, though fungal sources also exist. In cancer research, its importance is driven mainly by mucoadhesion, protonatable amines, cargo complexation, endosomal interaction, and formulation-tunable immune and tumor-microenvironment effects; biological behavior depends strongly on molecular weight, degree of deacetylation, pattern of substitution, and formulation architecture. Low–molecular weight chitosan and modified forms have also been reported to inhibit angiogenesis, modulate tumor microenvironment acidity, interfere with metastasis, and induce apoptosis in some in vitro systems. A major translational role of chitosan is as a nanoparticle carrier for chemotherapeutics, genes, and immunotherapies, improving stability and targeted delivery. Effects vary significantly depending on molecular weight, degree of deacetylation, and formulation. Primary mechanisms (ranked): Chitosan has been shown to inhibit the growth of various types of cancer cells, including breast, lung, and colon cancer cells.Chitosan has been shown to inhibit angiogenesis, stimulate the immune system, and anti-inflammatory. Chitosan is only soluble in acidic settings, hence limiting its use in neutral or alkaline pH circumstances
Bioavailability / PK relevance: Chitosan is not a conventional systemically bioavailable small molecule. Native CS has limited neutral-pH solubility and its translational behavior is dominated by route, particle size, surface chemistry, molecular weight, and degree of deacetylation. Oncology relevance is strongest in local, mucosal, intratumoral, hydrogel, nanoparticle, and carrier-based applications rather than free systemic exposure. In-vitro vs systemic exposure relevance: Many direct in-vitro anticancer studies use concentrations, contact conditions, or modified chitosan constructs that are not straightforwardly comparable to achievable systemic exposure of native CS. Therefore, carrier/platform effects and local-delivery applications are more clinically plausible than relying on native chitosan as a systemic concentration-driven anticancer agent. Clinical evidence status: Predominantly preclinical for direct anticancer use. Human oncology evidence is limited and mostly adjunctive, formulation-specific, or device/supportive-care related. There is no established regulatory status for chitosan as a standalone approved anticancer drug, although chitosan-containing or chitosan-derived oncology platforms and local immunotherapy approaches have entered early clinical investigation. Mechanistic pathway table
|
| Source: HalifaxProj(induce) |
| Type: |
| IL-12, an antitumor cytokine is considered to be a promising cytokine for enhancing an antitumor immune response. Interleukin-12 (IL-12) is a cytokine that plays a crucial role in the immune response, particularly in the activation of T cells and natural killer (NK) cells. It is produced by various immune cells, including macrophages and dendritic cells, and is known for its ability to promote the differentiation of T cells into a type that can effectively combat cancer cells. IL-12 is often expressed in various cancers, including melanoma, renal cell carcinoma, breast cancer, and colorectal cancer. Its expression can vary depending on the tumor type and the immune context. Tumor-infiltrating immune cells, particularly activated macrophages and dendritic cells, are significant sources of IL-12 in the tumor microenvironment. IL-12 is primarily known for its role in promoting anti-tumor immunity. It enhances the differentiation of naive T cells into T helper 1 (Th1) cells, which produce pro-inflammatory cytokines and support cytotoxic T cell responses. IL-12 also stimulates the activity of NK cells, enhancing their ability to kill tumor cells and produce additional cytokines, such as interferon-gamma (IFN-γ), which further promotes anti-tumor immunity. Low levels of IL-12 in the tumor microenvironment are often associated with poor anti-tumor immune responses and can correlate with worse clinical outcomes. In such cases, strategies to enhance IL-12 production or signaling may be beneficial for improving anti-tumor immunity. |
| 5986- | Chit, | The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells |
| - | Study, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:210 Target#:157 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid